IO University

Webinars


Upcoming Webinars:

This activity is supported by an education grant from Boston Scientific Corporation

Y90 Radioembolization - Use in Early Stage HCC and as Bridge to Transplant

Thursday, October 22, 2020 6:00pm - 7:00pm CDT

Length: 60 Minutes

Format: Round Table Discussion

The webinar will review indications, current developments, and practice of Y90 radioembolization, specifically focusing on use in early-stage HCC, radiation segmentectomy and use for bridge to transplant, focusing on UNOS T1/T2 stages. The panelists will specifically focus on discussing recent data in support of a “one-stop-shop Y90” and additionally focus on the of Y90 for liver regeneration and induction of liver remnant hypertrophy.

Learning Objectives: At the conclusion of the seminar, the audience will be able to:

  1. Understand current practice patterns and applications of Y90 in the setting of early-stage HCC
  2. Participate in conversations about recently published data on use of Y90 in UNOS T1/T2 stages 
  3. Identify potential limitations of the currently available scientific data and discuss strategies to address this in tumor-board-like conversations in their institutions.

Register Now

Moderators:

Riad Salem, MD, MBA
Northwestern University

David Maddoff, MD, PhD
Yale University

Panelists:

William Rilling, MD, FSIR
Medical College of Wisconsin

Nishita Kothary, MD
Stanford University

Greg Nadolski, MD
University of Pennsylvania

Nicholas Fidelman, MD
University of California San Francisco


CME Information



Jointly provided by The France Foundation and The Society of Interventional Oncology:

france.png

Target Audience:

This activity is intended for interventional radiologists, hepatologists, radiation, medical and surgical oncologists, transplant surgeons, and physicists who treat patients with hepatic malignances.

Statement of Need:

Hepatocellular carcinoma (HCC) is one of the fastest growing cancers worldwide. While early stage disease might be amenable to curative treatments, loco-regional and systemic therapy is used for the majority of cases with intermediate to advanced stage disease. Due to the lack of effective systemic therapies for HCC, researchers have been investigating the use of locoregional tumor control with Yttrium-90 (Y90) radioembolization. Currently, there are two approved available Y90 devices for administration and numerous ongoing trials aimed at exploring the current and future utility of radioembolization in hepatic malignancies. A new and special role for Y90 has been recently investigated in patients with early stage disease, specifically with UNOS Stage 1/2 as well as its use as a bridge to transplant. This activity will discuss the recently published data (Gabr A, Hepatology & Journal of Hepatology, 2020) and consider Y90 as a possible regional option for those conditions. This activity is developed to educate clinicians on newer evidence and how to apply the information to their current practice of treating patients with HCC.

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and The Society of Interventional Oncology. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.


Credit Designation:

Physicians:

The France Foundation designates this internet live course for a maximum of 1 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. This credit will be free to SIO members.

Method of Participation/How to Receive Credit:

  1. There are no fees for participating in and receiving credit for this activity as an SIO member.
  2. Review the activity objectives and CME/CE information.
  3. Participate in the CME/CE activity.
  4. Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  5. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credit(s)™ or a certificate of participation—your CME/CE certificate will be made available for download

Disclosure Policy:

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and The Society of Interventional Oncology (SIO) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and SIO resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and SIO seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and SIO are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Disclosure of Unlabeled Use:

TFF and SIO require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and SIO do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Activity Staff Disclosures:

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at The Society of Interventional Oncology who control content have no relevant financial relationships to disclose.

Faculty Disclosures-Activity Faculty:

The following faculty report that they have relevant financial relationships to disclose:

  • Dr. Riad Salem has consulted (non-CE) for Boston Scientific, Cook, Eisai, AstraZeneca, Sirtex, and Genentech. He serves as contract researcher for Boston Scientific.
  • Dr. David Madoff – disclosure t/c
  • Dr. William Rilling has consulted (non-CE) for B Braun, Boston Scientific, Terumo, BD/Bard, Sirtex, and Varian. He serves a contract researcher for Sirtex and Instylla.
  • Dr. Nicholas Fidelman has received research grants from Merck, Boston Scientific, and Sirtex.
  • Dr. Greg Nadolski – disclosure t/c
  • Dr. Nishita Kothary has consulted for Quantum Surgical and serves as contract researcher for EchoPixel. She is a stock holder of Neptune Medical.

Commercial Support Acknowledgment:

This activity is supported by an educational grant from Boston Scientific Corporation.

Disclaimer:

The France Foundation and The Society of Interventional Oncology present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, The Society of Interventional Oncology, and the commercial supporter assume no liability for the information herein.

Cryoablation and the Immune System - What We Need to Know for Clinical Practice

Tuesday, October 27, 2020 6:00pm-7:00pm CDT

Length: 60 Minutes

Format: Round Table Discussion

The webinar will review indications, current developments, and practice of cryoablation in interventional oncology. The panelists will discuss clinical applications and focus on abscopal effects/potential for immunological anti-tumor response following cryoablation.

Learning Objectives: At the conclusion of the seminar, the audience will be able to:

  1. Understand current practice patterns and applications of cryoablation in a variety of cancer
  2. Appreciate the complexity of currently available clinical trial and basic science data
  3. Identify potential use cases for cryoablation as well as gauge limitations of the technique

Register Now

Moderators:

Matthew Callstrom, MD, PhD
Mayo Clinic

Muneeb Ahmed, MD
Beth Israel Deaconess Medical Center

Panelists:

Isabel Newton, MD, PhD
University of California San Diego

Stephen Hunt, MD, PhD, DABR
University of Pennsylvania

Nariman Nezami, MD
Emory University

Andrew J. Gunn, MD
The University of Alabama at Birmingham


CME Information



Jointly provided by The France Foundation and The Society of Interventional Oncology:

france.png

Target Audience:

This activity is intended for interventional radiologists, hepatologists, radiation, medical and surgical oncologists, transplant surgeons, and physicists who treat patients with hepatic malignances.

Statement of Need:

Image guided cryoablation is a guideline approved and widely accepted therapeutic option for primary renal, lung and liver cancer as well as for oligo-metastatic disease to the bone and soft tissues. With the recent advent and growing interest in immunotherapy in solid tumors, possible synergistic effects of such therapies with cryoablation have been widely discussed and are currently under investigation. Specifically, cryoablation is thought to play a special role among all ablation modalities with respect to its ability to stimulate antigen exposure to the immune system and improve abscopal immune response. This activity is developed to educate clinicians on the most cutting edge research and possible novel applications of cryoablation in combination with immunotherapy for all of the aforementioned malignancies.

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and The Society of Interventional Oncology. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.


Credit Designation:

Physicians:

The France Foundation designates this internet live course for a maximum of 1 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. This credit will be free to SIO members.

Method of Participation/How to Receive Credit:

  1. There are no fees for participating in and receiving credit for this activity as an SIO member.
  2. Review the activity objectives and CME/CE information.
  3. Participate in the CME/CE activity.
  4. Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  5. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credit(s)™ or a certificate of participation—your CME/CE certificate will be made available for download

Disclosure Policy:

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and The Society of Interventional Oncology (SIO) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and SIO resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and SIO seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and SIO are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Disclosure of Unlabeled Use:

TFF and SIO require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and SIO do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Activity Staff Disclosures:

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at The Society of Interventional Oncology who control content have no relevant financial relationships to disclose.

Faculty Disclosures-Activity Faculty:

The following faculty report that they have relevant financial relationships to disclose:

  • Dr. Matthew Callstrom has consulted (non-CE) for Varian and Medtronic. He serves as contract researcher for Galil Medical.
  • Dr. Isabel Newton – disclosure t/c
  • Dr. Stephen Hunt has served on speakers bureau and consulted (non-CE) for Boston Scientific. He serves at contract researcher for Guerbet, BTG, and NIH. Dr. Hunt holds property rights/patent holder for PIGILab Research Ventures and is involved with the startup company Artificial Intel Med Imaging Enterprise (AIMIE).
  • • Dr. Andrew J. Gunn has consulted (Non-CE) for Boston Scientific and Varian. He serves on speakers bureau for Terumo and Boston Scientific. Dr. Gunn serves as contract researcher for Penumbra.

The faculty listed below report that they have no relevant financial relationships to disclose:

  • Dr. Muneeb Ahmed
  • Dr. Nariman Nezami

Commercial Support Acknowledgment:

This activity is supported by an educational grant from Boston Scientific Corporation.

Disclaimer:

The France Foundation and The Society of Interventional Oncology present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, The Society of Interventional Oncology, and the commercial supporter assume no liability for the information herein.

On-Demand: A Roundtable Discussion on the Multicenter LEGACY Study: Response Rate, Duration of Response and Overall Survival of Y90 in Early and Advanced HCC

The Society of Interventional Oncology (SIO) hosted a roundtable discussion of the multicenter LEGACY study, recently presented at CIRSE, on 15 September.

Participants had an opportunity to hear from the investigators of the study – in which Yttrium-90 glass microspheres in the treatment of early and advanced hepatocellular carcinoma are used– and discuss results in a live format via Zoom.

This activity is supported by an education grant from Boston Scientific Corporation

Moderator:

Riad Salem, MD, MBA
Professor of Radiology, Medicine, and Surgery Chief, Section of Vascular and Interventional Radiology
Vice-Chair, Image-Guided Therapy
Department of Radiology
Northwestern University

Panelists:

Guy Johnson, MD
Radiologist and Associate Professor of Radiology
University of Washington

Ed Kim, MD, FSIR
Associate Professor of Radiology and Surgery
Director, Interventional Oncology
Department of Radiology, Division of Interventional Radiology
Mount Sinai Health Systems

Siddarth Padia, MD
Specialist, Vascular and Interventional Radiology
Radiological Sciences Department
UCLA

Uei Pua, MBBS
Senior Consultant
Tan Tock Seng Hospital

How to Claim Your CME Credits

SIO Member Instructions

Please email education@sio-central for instructions on how to receive your CME Credits.

SIO Non-Member Instructions

Please follow the instructions below:

  1. Click here to log into your SIO online account *
  2. Click here and add your LEGACY Webinar CME credits to your shopping cart
  3. In the lower right corner of the webpage, click "add to cart"
  4. In the upper left corner of the webpage, click "view cart"
  5. Click "checkout"
  6. Review your billing information and click "OK"
  7. Complete your payment using your preferred payment method
  8. You will receive a confirmation email containing final instructions for obtaining your CME credits

* If you do not already have an SIO online account, you can create your free guest account by clicking here.

.


.

CME Information



Jointly provided by The France Foundation and The Society of Interventional Oncology:

france.png

Learning Objectives:

  • Discuss the objective response rates when assessed using blinded independent central review
  • Discuss the importance of duration of response
  • Review overall survival observed in early and advanced HCC
  • Synthesize how data from this study can impact clinical outcomes for patients with HCC

Target Audience:

This activity is intended for interventional radiologists, hepatologists, radiation, medical and surgical oncologists, transplant surgeons, and physicists who treat patients with hepatic malignancies.

Statement of Need:

Hepatocellular carcinoma (HCC) both primary and secondary affects millions of patient worldwide. While early stage disease might be amenable for curative treatments, chemotherapy is used for the majority of other cases. Due to the lack of effective systemic therapies for HCC, researchers have been investigating the use of locoregional tumor control with Yttrium-90 (Y90) radioembolization. Currently, there are two approved available Y90 devices for administration and numerous ongoing trials aimed at exploring the current and future utility of radioembolization in hepatic malignancies. As more information from studies are made available it is important to ensure clinicians are up to date with the latest evidence.  This activity is developed to educate clinicians on newer evidence and how to apply the information to their current practice of treating patients with hepatic malignancies.

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and The Society of Interventional Oncology. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.


Credit Designation:

Physicians:

The France Foundation designates this internet live course for a maximum of 1.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. This credit will be free to SIO members.

Method of Participation/How to Receive Credit:

  1. There are no fees for participating in and receiving credit for this activity as an SIO member.
  2. Review the activity objectives and CME/CE information.
  3. Participate in the CME/CE activity.
  4. Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  5. Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credit(s)™ or a certificate of participation—your CME/CE certificate will be made available for download

Disclosure Policy:

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and The Society of Interventional Oncology (SIO) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and SIO resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and SIO seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and SIO are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Disclosure of Unlabeled Use:

TFF and SIO require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and SIO do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Activity Staff Disclosures:

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at The Society of Interventional Oncology who control content have no relevant financial relationships to disclose.

Faculty Disclosures-Activity Faculty:

The following faculty report that they have relevant financial relationships to disclose:

  • Dr. Riad Salem has consulted (non-CE) for Boston Scientific, Cook, Eisai, AstraZeneca, Sirtex, and Genentech. He has contracted research for Boston Scientific.
  • Dr. Edward Kim has consulted (non-CE) for Boston Scientific and Bristol Myers Squibb. He has served on Speakers Bureau (non-CE) for Ethicon Neuwave and Boston Scientific. Dr. Kim has contracted research for Philips Healthcare.
  • Dr. Siddarth Padia has consulted (non-CE) for Boston Scientific and has contracted research for Varian Medical Systems.
  • Dr. Guy Johnson has consulted (non-CE) for Boston Scientific and Genentech.

The faculty listed below report that they have no relevant financial relationships to disclose:

  • Dr. Uei Pua

Commercial Support Acknowledgment:

This activity is supported by an educational grant from Boston Scientific Corporation.

Disclaimer:

The France Foundation and The Society of Interventional Oncology present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, The Society of Interventional Oncology, and the commercial supporter assume no liability for the information herein.

2020CIO-SIO-728x90.jpg